BSEGENPHARMASEC LIMITED· Commercial Services & SuppliesHighNeutral
Announced Tue, 11 Aug, 2026 · 16:08 IST

Q1 FY27 Results: Revenue up 269% YoY standalone, PAT nearly flat

Revenue Growth 20pctResults View source PDFExplain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-2.9%Reaction day
₹1.05
prior close
₹1.03
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+0.4%-3.2% vs market
Trading & Distributors peers, median of 133sector+0.0%-2.9% vs sector

On the reaction day the stock moved 3.2 pts less than Nifty Microcap 250 and 2.9 pts less than its Trading & Distributors peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+1.0
10m
-1.0
15m
+1.0
30m
+0.0
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-2.9+0.4-3.2+0.0-2.9
Next day
-2.9+0.5-3.4+0.0-2.9
2d
-2.9+0.6-3.5+0.0-2.9
3d
-3.8+0.7-4.5-0.5-3.3
4d
-2.9+1.1-4.0-1.0-1.8
5d
-3.8+0.5-4.3-1.3-2.5
1w
-2.9+1.3-4.2-0.9-2.0
15d
+17.1+0.5+16.6-2.1+19.2
1m
+8.6-0.8+9.4-3.8+12.4
2m
-2.9-0.9-1.9-6.4+3.5
3m
—————
UpDownMarket · Nifty Microcap 250Sector · Trading & Distributors peers, median of 133Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Genpharmasec posted Q1 FY27 (quarter ended June 30, 2026) standalone revenue of Rs. 4,474.44 lakhs, up about 269% from Rs. 1,211.32 lakhs in Q1 FY26. Profit after tax was nearly flat at Rs. 156.96 lakhs vs Rs. 155.52 lakhs. Consolidated revenue rose to Rs. 4,971.03 lakhs but consolidated PAT fell sharply to Rs. 22.60 lakhs from Rs. 117.81 lakhs. Auditor changed to Bilimoria Mehta and Co from prior year auditor Abhishek S Tiwari and Associates.

Likely market impact

Strong revenue growth but margin pressure at consolidated level. PAT flat standalone, down sharply consolidated. New auditor noted.